Drugs / naquotinib
naquotinib
also known as
ASP8273 · ASP-8273 MESILATE · ASP-8273 MESYLATE · naquotinib mesilate · NAQUOTINIB MESYLATE
Small molecule targets EGFR via inhibition
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03082300 | Mar → May 2017 | non-small cell lung carcinoma | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02674555 | Nov 2016 | cancer | Astellas Pharma Global Development, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02113813 | Apr 2014 → Jul 2017 | non-small cell lung carcinoma | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02192697 | Jan 2014 → Jan 2016 | non-small cell lung carcinoma | Astellas Pharma Inc | Terminated | No outcome recorded Stop: Enrollment |
| Phase 22 trials | ||||||
| Phase 2 | NCT03042013 | Feb 2017 | lung cancer | Astellas Pharma Global Development, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02500927 | Jun 2015 → Jun 2017 | — | Astellas Pharma Inc | Terminated | No outcome recorded Stop: Enrollment |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT02588261 | Feb 2016 → Dec 2017 | non-small cell lung carcinoma | Astellas Pharma Global Development, Inc. | Terminated | Missed primary Stop: Enrollment |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-05-11 | Astellas Pharma Inc | Astellas Announces Decision to Discontinue ASP8273 Treatment and Close Randomization for Clinical Study Protocol 8273-CL-0302 astellas.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | naquotinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02674555 ↗ |
| Known as | ASP-8273 MESILATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3663929 ↗ |
| Known as | ASP-8273 MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3663929 ↗ |
| Known as | ASP8273 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02192697 ↗ |
| Known as | naquotinib mesilate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02588261 ↗ |
| Known as | NAQUOTINIB MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3663929 ↗ |
| Action | Inhibit | “inhibits EGFR activating mutations” PMID 29807396 ↗ Jun 2018 |
| Modality | Small molecule | “ASP8273 is an irreversible EGFR-TKI” PMID 29807396 ↗ Jun 2018 |
| Route | Oral | “Oral administration” NCT02192697 ↗ |
| Target | EGFR | “inhibits EGFR activating mutations” PMID 29807396 ↗ Jun 2018 |